GlassScriptPhysician profile
Melissa Sj Mark
NPI 1942438916
$2,836.75
in general payments reported to CMS, 2019-2025
11 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $16.59 · 2021: $25.45 · 2022: $49.79 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,430 · Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,430.00 |
| Food and Beverage | $120.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Day One Biopharmaceuticals | $2,476.05 | 2025 | Ojemda |
| Shire North American Group INC | $130.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.64 | 2025 | |
| Global Blood Therapeutics, INC. | $42.04 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $37.29 | 2019 | |
| Sobi, INC | $25.97 | 2019 | |
| Genzyme Corporation | $25.12 | 2022 | |
| Novocure INC. | $24.67 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.